Why Cytokinetics, Incorporated (CYTK) stock moved
Cytokinetics, Incorporated (CYTK) shares fell 0.5% to $62.99 as of November 1, 2026, a slight decline from the prior close of $63.31. BestStocks flagged the session as a major change for CYTK. The move is tied to company news. Below, we break down what changed for CYTK, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Company News
Cytokinetics scheduled to report Q3 2026 results November 4 with management conference call. Q3 earnings and guidance will reveal clinical progress, cash burn, and pipeline advancement for pipeline-dependent biotech.
What it means for Cytokinetics, Incorporated investors
For Cytokinetics, Incorporated investors, the recent signals add up to a bearish shift. Weighing against that: Negative session, down 0.5%; Cytokinetics, Incorporated moved -4.06% intraday from $72.45 to $69.51. Wall Street's consensus price target sits at $113.33, implying +79.9% upside from $62.99. BestStocks rates the overall signal quality weak (33/100). With earnings roughly 3 days out, the next report is the most likely near-term test of the move.
CYTK price reaction
CYTK last traded at $62.99, down $0.32 (-0.51%) from the previous close of $63.31. The session traded on 0.6× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $60.73 and $65.62, and it currently sits about 46% of the way up that band.
Bullish and bearish analyst opinions on Cytokinetics, Incorporated (CYTK)
The consensus analyst price target on Cytokinetics, Incorporated (CYTK) is $113.33, 79.9% above the recent $62.99. Over the past 90 days analysts logged 0 upgrades, 9 maintains, and 0 downgrades. Here is how the bullish and bearish cases on CYTK line up.
The bullish case
- Wall Street's consensus price target of $113.33 implies +79.9% upside from $62.99.
- The Street's most bullish target is $140.00 (+122.3%).
The bearish case
- Negative session, down 0.5%.
- Cytokinetics, Incorporated moved -4.06% intraday from $72.45 to $69.51.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 1, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for CYTK
In-depth CYTK event analyses
Frequently asked questions about CYTK
Why did Cytokinetics, Incorporated (CYTK) stock move?
CYTK fell 0.5% to $62.99. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did CYTK stock fall?
CYTK lost 0.51% ($0.32) versus the prior close of $63.31, last trading at $62.99 on 0.6× average volume.
When is Cytokinetics, Incorporated's next earnings date?
CYTK's next earnings report is estimated for 2026-11-04 — about 3 days away.
What is the analyst price target for CYTK?
The consensus analyst price target for CYTK is $113.33, about 79.9% above the current $62.99. Over the past 90 days, analysts recorded 0 upgrades, 9 maintains, and 0 downgrades.
How BestStocks tracks CYTK
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for CYTK, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 1, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
